Postoperative chemoradiotherapy in high risk locally advanced gastric cancer
- PMID: 23346541
- PMCID: PMC3546290
- DOI: 10.3857/roj.2012.30.4.213
Postoperative chemoradiotherapy in high risk locally advanced gastric cancer
Abstract
Purpose: To evaluate treatment outcome of patients with high risk locally advanced gastric cancer after postoperative chemoradiotherapy.
Materials and methods: Between May 2003 and May 2012, thirteen patients who underwent postoperative chemoradiotherapy for gastric cancer with resection margin involvement or adjacent structure invasion were retrospectively analyzed. Concurrent chemotherapy was administered in 10 patients. Median dose of radiation was 50.4 Gy (range, 45 to 55.8 Gy).
Results: The median follow-up duration for surviving patients was 48 months (range, 5 to 108 months). The 5-year overall survival rate was 42% and the 5-year disease-free survival rate was 28%. Major pattern of failure was peritoneal seeding with 46%. Locoregional recurrence was reported in only one patient. Grade 2 or higher gastrointestinal toxicity occurred in 54% of the patients. However, there was only one patient with higher than grade 3 toxicity.
Conclusion: Despite reported suggested role of adjuvant radiotherapy with combination chemotherapy in gastric cancer, only very small portion of the patients underwent the treatment. Results from this study show that postoperative chemoradiotherapy provided excellent locoregional control with acceptable and manageable treatment related toxicity in patients with high risk locally advanced gastric cancer. Thus, postoperative chemoradiotherapy may improve treatment result in terms of locoregional control in these high risk patients. However, as these findings are based on small series, validation with larger cohort is suggested.
Keywords: Adjuvant chemoradiotherapy; Local; Neoplasm recurrence; Stomach neoplasm.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures
Similar articles
-
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. doi: 10.1016/j.ijrobp.2005.09.017. Epub 2006 Jan 18. Int J Radiat Oncol Biol Phys. 2006. PMID: 16414206 Clinical Trial.
-
The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.World J Surg Oncol. 2017 Nov 22;15(1):205. doi: 10.1186/s12957-017-1275-4. World J Surg Oncol. 2017. PMID: 29166925 Free PMC article. Clinical Trial.
-
Extensive surgery after high-dose preoperative chemoradiotherapy for locally advanced recurrent rectal cancer.Dis Colon Rectum. 2000 Mar;43(3):312-9. doi: 10.1007/BF02258294. Dis Colon Rectum. 2000. PMID: 10733111
-
Retrospective analysis of treatment outcomes after postoperative chemoradiotherapy in advanced gastric cancer.Radiat Oncol J. 2011 Dec;29(4):252-9. doi: 10.3857/roj.2011.29.4.252. Epub 2011 Dec 28. Radiat Oncol J. 2011. PMID: 22984678 Free PMC article.
-
Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.Hematol Oncol Clin North Am. 2004 Feb;18(1):41-53. doi: 10.1016/s0889-8588(03)00138-2. Hematol Oncol Clin North Am. 2004. PMID: 15005280 Review.
Cited by
-
A phase II trial of post-operative chemoradiotherapy for completely resected gastric cancer with D2 lymphadenectomy.Oncol Lett. 2014 Oct;8(4):1844-1848. doi: 10.3892/ol.2014.2382. Epub 2014 Jul 25. Oncol Lett. 2014. PMID: 25202423 Free PMC article.
-
Effects of extended lymphadenectomy and postoperative chemotherapy on node-negative gastric cancer.World J Gastroenterol. 2013 Sep 7;19(33):5551-6. doi: 10.3748/wjg.v19.i33.5551. World J Gastroenterol. 2013. PMID: 24023500 Free PMC article.
-
Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: is radiotherapy necessary after D2-dissection?World J Gastroenterol. 2014 Sep 28;20(36):12900-7. doi: 10.3748/wjg.v20.i36.12900. World J Gastroenterol. 2014. PMID: 25278687 Free PMC article. Review.
-
Isolated ovarian metastasis of gastric cancer: Krukenberg tumor.Contemp Oncol (Pozn). 2013;17(6):515-9. doi: 10.5114/wo.2013.37542. Epub 2013 Dec 19. Contemp Oncol (Pozn). 2013. PMID: 24592139 Free PMC article.
-
A Case Report of Salvage Radiotherapy for a Patient with Recurrent Gastric Cancer and Multiple Comorbidities Using Real-time MRI-guided Adaptive Treatment System.Cureus. 2018 Apr 12;10(4):e2471. doi: 10.7759/cureus.2471. Cureus. 2018. PMID: 29900091 Free PMC article.
References
-
- GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729–1737. - PubMed
-
- Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–321. - PubMed
-
- Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28:2430–2436. - PubMed
LinkOut - more resources
Full Text Sources